Výsledky vyhledávání - "A.G.G Turpie"

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Two-year outcomes of patients with atrial fibrillation treated with rivaroxaban: results from RIVER registry

Autor: K.A.A Fox, Karen S. Pieper, Jan Beyer-Westendorf, Saverio Virdone, J.-Y. Le Heuzey, Bernard J. Gersh, Ajay K. Kakkar, Sylvia Haas, Gloria Kayani, River Investigators, A.G.G Turpie, Alan John Camm

Publikováno v: European Heart Journal. 42

Introduction Non-vitamin-K oral anticoagulants (NOACs) were recommended in preference to oral vitamin K antagonists (VKAs) in the 2020 updated guidelines for stroke prevention in atrial fibrillation (AF), from the European Society of Cardiology (ESC)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bc005412bac0f72091dd972e80ab23b7
https://doi.org/10.1093/eurheartj/ehab724.0578

Zobrazit plný text záznamu

Comparative effectiveness of NOAC vs VKA in patients representing common clinical challenges: results from the GARFIELD-AF registry

Autor: Karen S. Pieper, Samuel Z. Goldhaber, A.G.G Turpie, Shinya Goto, K.A.A Fox, Alan John Camm, Sylvia Haas, Ajay K. Kakkar, David Fitzmaurice, J.C.L Himmelreich, Frank Misselwitz, Saverio Virdone, J.-P Bassand, Freek W.A. Verheugt, Garfield-Af Investigators, Gloria Kayani

Publikováno v: European Heart Journal. 42

Introduction Large phase III trials of non-valvular atrial fibrillation (AF) patients have shown a favourable risk-to-benefit ratio with Non-Vitamin K antagonist oral anticoagulants (NOAC) compared to Vitamin K antagonists (VKA). Although the results

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::405b7cdab7c32470c6ec79484a256588
https://doi.org/10.1093/eurheartj/ehab724.0557

Zobrazit plný text záznamu

Impact of NOAC and VKA on outcome of patients with newly diagnosed atrial fibrillation and diabetes: a report from the GARFIELD-AF registry

Autor: Freek W.A. Verheugt, Garfield-Af Investigators, Samuel Z. Goldhaber, K.A.A Fox, Alan John Camm, J.-P Bassand, Shinya Goto, A.G.G Turpie, Werner Hacke, Karen S. Pieper, Frank Misselwitz, Frank Cools, Gloria Kayani, Saverio Virdone, Sylvia Haas, Ajay K. Kakkar

Publikováno v: European Heart Journal. 42

Introduction Diabetes mellitus (DM) is one of the most common comorbidities observed in patients with atrial fibrillation (AF). It is associated with increased risks of stroke/SE and death. Purpose To assess the impact of NOAC and VKA on outcomes of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::07ace3baddcef14903d316778df9d73b
https://doi.org/10.1093/eurheartj/ehab724.0468

Zobrazit plný text záznamu

Rivaroxaban dosing in patients with atrial fibrillation: results from the RIVER registry – is dosing according to renal function appropriate?

Autor: K.A.A Fox, Saverio Virdone, Gloria Kayani, A.G.G Turpie, Sylvia Haas, J.-Y. Le Heuzey, River Investigators, Bernard J. Gersh, Jan Beyer-Westendorf, Alan John Camm, Karen S. Pieper, Ajay K. Kakkar

Publikováno v: European Heart Journal. 42

Introduction Rivaroxaban is recommended as an option for anticoagulation in patients with nonvalvular atrial fibrillation (AF) with one or more risk factors for stroke. The approved/recommended rivaroxaban dose for stroke prevention in patients with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a6321491001ffc40389122388c19fc54
https://doi.org/10.1093/eurheartj/ehab724.0558

Zobrazit plný text záznamu

Safety and efficacy of apixaban and rivaroxaban versus warfarin in real-world atrial fibrillation patients are similar to their randomized trials: insights from GARFIELD-AF registry

Autor: Karen S. Pieper, Garfield-Af Investigators, J.C.L Himmelreich, A.G.G Turpie, Alan John Camm, Samuel Z. Goldhaber, Ajay K. Kakkar, Sylvia Haas, J.-P Bassand, K.A.A Fox, Shinya Goto, Frank Misselwitz, Saverio Virdone, David Fitzmaurice, Ralf E. Harskamp, Freek W.A. Verheugt

Publikováno v: European Heart Journal. 42

Introduction Generalisability of patient selection in the landmark trials for the approval of apixaban (ARISTOTLE) and rivaroxaban (ROCKET AF) for use in non-valvular atrial fibrillation (AF) is limited. Although observational data have confirmed the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::cc18e51aa05db2c1dff09ea73bc93d86
https://doi.org/10.1093/eurheartj/ehab724.0559

Zobrazit plný text záznamu

Permanent discontinuation of different anticoagulants in patients with atrial fibrillation and the impact on clinical outcome: data from the GARFIELD-AF registry

Autor: Ajay K. Kakkar, Gloria Kayani, Garfield-Af Investigators, Frank Cools, Sylvia Haas, K.A.A Fox, Alan John Camm, Shinya Goto, J.-P Bassand, F. W. A. Verheugt, David W. Johnson, Karen S. Pieper, A.G.G Turpie, Samuel Z. Goldhaber, Frank Misselwitz, David Fitzmaurice

Publikováno v: European Heart Journal. 41

Background Non-Vitamin K Antagonists (NOAC) are replacing vitamin K Antagonists (VKA) as first line oral anticoagulant therapy (OAC) in patients with non-valvular atrial fibrillation (NVAF). Discontinuation of OAC might put patients at increased risk

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3a6db6b53d290c4411b7aaaeeecabe3f
https://doi.org/10.1093/ehjci/ehaa946.0639

Zobrazit plný text záznamu

Guideline-directed medical therapies for comorbidities among patients with atrial fibrillation: results from GARFIELD-AF

Autor: A.G.G Turpie, Ajay K. Kakkar, David Fitzmaurice, J.-P Bassand, Frank Misselwitz, Samuel Z. Goldhaber, Alan John Camm, Gloria Kayani, Shinya Goto, Freek W.A. Verheugt, Garfield-Af Investigators, Sylvia Haas, Karen S. Pieper, Jan Steffel, Saverio Virdone, K.A.A Fox

Publikováno v: European Heart Journal. 41

Introduction The GARFIELD-AF registry is a prospective, multicentre, observational study of adults with recently diagnosed non-valvular atrial fibrillation (AF) and at least one risk factor for stroke. In GARFIELD-AF the absolute risk reduction of mo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f31af985972a4ecc21a8cb352e2200d4
https://doi.org/10.1093/ehjci/ehaa946.0631

Zobrazit plný text záznamu

Clinical outcomes of patients with newly diagnosed atrial fibrillation who refused anticoagulation: findings from the global GARFIELD-AF registry

Autor: Shinya Goto, Ajay K. Kakkar, K.A.A Fox, Gloria Kayani, Karen S. Pieper, David Fitzmaurice, Freek W.A. Verheugt, Saverio Virdone, Sylvia Haas, Garfield-Af Investigators, J.-P Bassand, Frank Misselwitz, Alan John Camm, Patricia N. Apenteng, A.G.G Turpie, Samuel Z. Goldhaber

Publikováno v: European Heart Journal. 41

Introduction Atrial fibrillation (AF) remains a common cause of stroke and anticoagulation (AC) treatment reduces the risk of stroke. Reasons for patients with AF not receiving anticoagulation are generally attributed to the clinician decision, howev

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a88dceae106aa9917cbaf213028ca881
https://doi.org/10.1093/ehjci/ehaa946.0517

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání